Army Awards AeroVironment $464.8M Laser Weapon Contract

What happened

The U.S. Army awarded AeroVironment a $464.8 million contract for its LOCUST X3 30-kilowatt laser weapon system, expanding the company's directed-energy portfolio and reinforcing its counter-drone offerings. This award follows the recent $500 million Domestic Shield IDIQ and $80.5 million Titan task order, further validating demand for counter-UAS solutions as DoD budget priorities shift toward directed energy and low-cost interceptors. The contract likely falls under the Space, Cyber, and Directed Energy (SCDE) segment, which has struggled with profitability, posting negative adjusted EBITDA in FY26 and suffering a $240.7 million goodwill impairment after the SCAR termination. While the new award strengthens the revenue pipeline, it does not remedy the company's operational challenges: gross margin fell to 32% in Q4 FY26, integration of BlueHalo and ESAero remains incomplete, and internal control weaknesses persist. Investors should treat the contract as positive demand confirmation but not as a solution to execution and reporting quality issues that have kept the stock in a WAIT rating.

Implication

The $464.8 million award increases confidence in the counter-UAS and directed-energy growth narrative, but its revenue contribution will likely be recognized over several years and may carry lower margins typical of development programs. The SCDE segment's negative EBITDA and prior impairment make it critical for investors to track whether this award improves segment profitability or merely adds revenue without bottom-line benefit. Existing concerns around backlog conversion, with FY27 guidance requiring roughly $0.9-$1.0 billion beyond funded backlog, remain central; this award reduces that gap somewhat but does not guarantee smooth execution. The company must also demonstrate progress on internal controls and integration, as adverse ICFR opinions and restatements have undermined reporting credibility and valuation multiple. Until the company shows two consecutive quarters of clean execution with improving margins, the stock is likely to remain range-bound; consider adding near $145 if fundamentals improve, or reassess after the next earnings report.

Thesis delta

This contract strengthens the demand side of the thesis but does not address the execution and control concerns that underpin the WAIT rating. The investment case now leans more on backlog conversion and margin recovery, but the overhang from material weaknesses and integration risk remains. A shift to a more constructive stance would require evidence of sustained margin improvement and clean reporting in upcoming filings.